Autoantibodies to ribosomal P proteins in systemic lupus erythematosus

Yalaoui, S.; Gorgi, Y.; Hajri, R.; Goucha, R.; Chaabouni, L.; Kooli, C.; Ayed, K.

doi:10.1016/s1297-319x(02)00366-4

Cited by 10 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we studied their association with major clinical characteristics. As mentioned before, there existed relationship between major clinical manifestations and lupus-related autoantibodies in SLE patients [9][10][11][12], for example, anti-dsDNA and nephritis, anti-SM and skin damage, myositis and central nervous system disorder, AnuA and nephritis as well as neurologic disorder, etc., while rRNP was recognized to be correlated with neurologic disorder, liver involvement and LN. Our study demonstrates significant association of rRNP with photaesthesia and AHA with nephritis.…”

Section: Discussionmentioning

confidence: 86%

Prevalence and clinical significance of 15 autoantibodies in patients with new-onset systemic lupus erythematosus

Pan

et al. 2010

Ir J Med Sci

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 86%

Prevalence and clinical significance of 15 autoantibodies in patients with new-onset systemic lupus erythematosus

Pan

et al. 2010

Ir J Med Sci

View full text Add to dashboard Cite

show abstract

“…Twenty‐four additional publications (6, 8–13, 15–20, 22, 23, 25–29, 31–34) were retrieved from the database search, representing a total of 38 studies involving 3,713 lupus patients. Nevertheless, data for the comparison of NPSLE versus non‐NPSLE groups were available in only 18 of the 24 additional studies; data for other comparisons were available in even fewer reports (Table 3).…”

Section: Resultsmentioning

confidence: 99%

“…During the last 2 decades, several studies have explored the utility of antibodies to ribosomal P proteins (anti‐P) in detecting NPSLE (6, 8–35). These antibodies are directed toward 3 large‐subunit ribosomal phosphoproteins, called P0 (38 kd), P1 (19 kd), and P2 (17 kd), which share a common linear determinant in the carboxyl‐terminal 22–amino acid sequence (36).…”

mentioning

confidence: 99%

Accuracy of anti–ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: An international meta‐analysis

Karassa¹,

Afeltra²,

Ambrožič³

et al. 2005

Arthritis & Rheumatism

202

106

View full text Add to dashboard Cite

Objective. To quantitatively evaluate the diagnostic accuracy of antibodies to ribosomal P proteins (anti-P) for neuropsychiatric systemic lupus erythematosus (NPSLE) in general, for psychosis, mood disorder, or both, and for other diffuse manifestations.Methods. This international meta-analysis combined standardized data from 1,537 lupus patients contributed by 14 research teams. Weighted estimation of sensitivity and specificity with fixed-effects and random-effects models, as well as summary receiver operating characteristic (SROC) curve analysis, was used to summarize test performance. The robustness of the overall estimates was examined in sensitivity analyses that included additional studies published up to November 1, 2004 in the Medline, EMBase, and Cochrane databases.Results. Combining the data from the 14 teams, the weighted sensitivity and specificity estimates for the diagnosis of NPSLE were 26% (95% confidence interval [95% CI] 15-42%) and 80% (95% CI 74-85%), respectively. For psychosis, mood disorder, or both, the sensitivity and specificity were 27% (95% CI 14-47%) and 80% (95% CI 74-85%), respectively. For other diffuse manifestations, the sensitivity was 24% (95% CI 12-42%), and the specificity was 80% (95% CI 73-85%). The proportion of patients with anti-P antibodies did not vary markedly across different presentations of NPSLE. Between-study heterogeneity was substantial, but the SROC curves were consistent with the weighted estimates. In further analyses that included another 24

show abstract

“…The HLA-DR3 phenotype has been detected in approximately 70% of patients with SCLE and psoriasiform lesions. 71 Anti-U1RNP antibodies are present in the serum of patients with MCTD and SLE. These antibodies are detected in 100% of patients with MCTD and in approximately 30% of patients with SLE, but may also occur in neonatal lupus and, very rarely, in systemic sclerosis.…”

Section: Discussionmentioning

confidence: 99%

Lúpus eritematoso cutâneo: aspectos clínicos e laboratoriais

Berbert

Mantese

2005

An. Bras. Dermatol.

View full text Add to dashboard Cite

Lupus erythematosus is a connective tissue autoimmune disorder that demonstrates systemic, cutaneous, or both systemic and cutaneous manifestations. Cutaneous lesions are classified as specific and nonspecific. The variety of clinical manifestations of the disease is reflected in the broad spectrum of laboratory patterns. In this article we describe the distinct subsets of cutaneous lupus erythematosus, correlating them with histopathological, direct immunofluorescence and serological findings. Keywords: Skin diseases; Autoimmune diseases; Collagen diseases; Connective tissue diseases; Lupus erythematosus, Cutaneous/classification; Lupus erythematosus, Cutaneous/diagnosis. Resumo: O lúpus eritematoso é doença auto-imune do tecido conjuntivo que reúne manifestações exclusivamente cutâneas ou multissistêmicas, podendo apresentar exuberância de auto-anticorpos. As lesões cutâneas do lúpus eritematoso são polimorfas e podem ser específicas ou inespecíficas. A diversidade de manifestações clínicas da doença reflete-se no amplo espectro de achados laboratoriais. Este artigo descreve as variadas formas clínicas do lúpus eritematoso cutâneo correlacionan

show abstract

Autoantibodies to ribosomal P proteins in systemic lupus erythematosus

Cited by 10 publications

References 13 publications

Prevalence and clinical significance of 15 autoantibodies in patients with new-onset systemic lupus erythematosus

Prevalence and clinical significance of 15 autoantibodies in patients with new-onset systemic lupus erythematosus

Accuracy of anti–ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: An international meta‐analysis

Lúpus eritematoso cutâneo: aspectos clínicos e laboratoriais

Contact Info

Product

Resources

About